Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases

BACKGROUND: Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer. METHODS: One thousand two hundred and fifty patients with newly diagnosed brain metastases (BM) were identified from the Vienna Brain Metastasis Registry. RESULTS: PLR and CRP/Alb were higher in patients with progressive extracranial disease and lower in patients with no evidence of extracranial disease. Lower NLR (cut-off = 5.07; 9.3 vs. 5.0 months), LLR (cut-off = 5.76; 10.0 vs. 5.3 months), PLR (cut-off = 335; 8.0 vs. 3.8 months), MLR (cut-off = 0.53; 6.0 vs. 3.5 months) and CRP/Alb (cut-off = 2.93; 8.5 vs. 3.7 months; p(adj) < 0.05) were associated with longer overall survival (OS). In multivariate analysis with graded prognostic assessment (hazard ratio (HR) 1.45; 95% confidence interval (CI): 1.32–1.59; p(adj) = 1.62e − 13()), NLR (HR 1.55; 95% CI: 1.38–1.75; p(adj) = 1.92e − 11), LLR (HR 1.57; 95% CI: 1.39–1.77; p(adj) = 1.96e − 11()), PLR (HR 1.60; 95% CI: 1.39–1.85; p(adj) = 2.87955e − 9), MLR (HR 1.41; 95% CI: 1.14–1.75; p(adj) = 0.027) and CRP/Alb (HR 1.83; 95% CI: 1.54–2.18; p(adj) = 2.73e − 10) remained independent factors associated with OS at BM diagnosis. CONCLUSIONS: Systemic inflammation, measured by NLR, LLR, PLR, MLR and CRP/Alb, was associated with OS in patients with BM. Further exploration of immune modulating therapies is warranted in the setting of BM.